Postsynaptic density protein 95 (PSD-95) is essential for synaptic maturation and plasticity. Although its synaptic regulation has been widely studied, the control of PSD-95 cellular expression is not understood. We found that Psd-95 was controlled posttranscriptionally during neural development. Psd-95 was transcribed early in mouse embryonic brain, but most of its product transcripts were degraded. The polypyrimidine tract binding proteins PTBP1 and PTBP2 repressed Psd-95 (also known as Dlg4) exon 18 splicing, leading to premature translation termination and nonsense-mediated mRNA decay. The loss of first PTBP1 and then of PTBP2 during embryonic development allowed splicing of exon 18 and expression of PSD-95 late in neuronal maturation. Re-expression of PTBP1 or PTBP2 in differentiated neurons inhibited PSD-95 expression and impaired the development of glutamatergic synapses. Thus, expression of PSD-95 during early neural development is controlled at the RNA level by two PTB proteins whose sequential downregulation is necessary for synapse maturation.
a r t I C l e S PSD-95 is an abundant scaffold protein of excitatory synapses, where it functions to cluster proteins such as glutamate receptors on the postsynaptic membrane and couple them with downstream signaling molecules 1, 2 . Psd-95 −/− mice have severe learning defects and exhibit both facilitation of long-term potentiation and disruption of longterm depression 3, 4 . The increase in PSD-95 expression during development is important for the maturation of excitatory synapses [5] [6] [7] [8] [9] . However, although the synaptic expression and post-translational modification of PSD-95 protein have been examined in relation to neuronal plasticity, there is little understanding of how its cellular expression is regulated during development.
Neuronal differentiation and maturation require an orchestrated series of complex genetic regulatory events. The roles of transcriptional and miRNA-mediated post-transcriptional control in this process are widely studied and are best understood. The contributions of other genetic regulatory mechanisms to neural development are not as well defined. Notably, the splicing of many transcripts is altered during neuronal differentiation. These regulated splicing events change the structure and activity of many proteins in a manner that is often highly conserved across species. However, the manner in which these isoform changes affect the differentiating neuron is largely unknown. Many of these neuron-specific alternative splicing events are controlled by the polypyrimidine tract binding proteins PTBP1 and PTBP2 (refs. 10, 11) . PTBP1 is highly expressed in non-neuronal cells and neural progenitor cells. Its downregulation in differentiating neurons alters the splicing of many exons to produce a neuron-specific repertoire of functional proteins. The downregulation of PTBP1 also induces expression of its homolog, PTBP2 (also known as brPTB or nPTB) [10] [11] [12] . These two similar proteins equally affect some exons, whereas other exons are more responsive to PTBP1 and thus change their splicing when these two proteins are exchanged during differentiation.
In addition to altering protein structure and function, alternative splicing can alter reading frame to induce translation termination and subsequent nonsense-mediated mRNA decay (NMD) of the spliced isoform. The NMD pathway allows the degradation of nonsense and frame-shift mutant mRNAs, preventing production of truncated protein products 13, 14 . NMD also acts as a quality control process to eliminate aberrantly spliced mRNAs. In addition, many splicing regulators limit their own expression through the autoregulation of their splicing to produce an NMD-targeted mRNA (alternative splicing-induced NMD, AS-NMD) 15, 16 . In addition to these splicing regulatory proteins, microarray studies have found additional transcripts that are induced when NMD is inhibited in mammalian cells [16] [17] [18] . Some of these transcripts integrate NMD into stress responses and nutrient homeostasis 19, 20 .
To understand the functional importance of PTBP1-mediated regulation during neuronal differentiation, we examined the physiological consequences of its reintroduction into differentiated neurons. Ectopic expression of PTBP1 did not alter neuronal cell fate, but strongly decreased PSD-95 protein expression. By examining the mechanism of this PSD-95 repression, we found that Psd-95 mRNA was transcribed throughout embryonic development, but was subject to intense post-transcriptional repression by the two PTB proteins and the NMD pathway. a r t I C l e S infected primary cortical cultures at 4 d in vitro (DIV) with lentivirus expressing Flag-tagged PTBP1 and GFP. At 4 DIV, >95% of cells in the cultures expressed the neuronal marker Tuj1 and were committed to the neuronal cell lineage (Supplementary Fig. 1 ). We found that cultures infected with PTBP1 virus differentiated normally and appeared to be almost morphologically identical at 12 DIV to those infected with control virus expressing GFP alone. Assessing several neuron-specific markers in the PTBP1-expressing neurons, we found a substantial reduction in PSD-95 protein levels. The repression was specific to PSD-95, as the expression of the PSD-95 homologs PSD-93 and SAP102 was not affected ( Fig. 1a,b ).
PTBP2 is induced as neural progenitors differentiate and PTBP1 is depleted. Re-expression of PTBP1 also repressed PTBP2. The repression of PSD-95 by PTBP1 could thus be a result of a decrease in PTBP2. However, infecting cultures with a PTBP2 lentivirus had equivalent effects to PTBP1 in repressing PSD-95 proteins at 12 DIV ( Fig. 1a,b) .
The lentiviral infections were very efficient, with most of the neurons in the culture expressing PTBP1 or PTBP2. To observe the effect of the PTB proteins on single cell morphology and to confirm that the observed PSD-95 repression was autonomous to neurons expressing either of the PTB proteins, we co-transfected primary cortical cultures with PTB expression plasmids and a GFP expression plasmid. This allowed Flag-tagged PTBP1 or PTBP2 expression in sporadic cells of the primary cultures. The GFP-positive cells all expressed exogenous PTB proteins, as measured by co-staining with antibody to Flag. We compared PSD-95 protein levels in the GFPpositive neurons at 12 DIV with those of neighboring GFP-negative neurons by immunofluorescent staining and confocal microscopy ( Fig. 1c) . Both the total PSD-95 fluorescence in the soma (Fig. 1d ) and the average PSD-95 voxel intensity relative to cell volume ( Supplementary Fig. 2 ) were decreased by 50% in the PTBP1expressing cells. A control vector had no effect on PSD-95 protein expression. Transfection with a Flag-tagged PTBP2 expression plasmid had the similar effect of reducing PSD-95 protein levels ( Fig. 1c,d) . To examine whether PTBP1 or PTBP2 also impaired synaptic expression of PSD-95 proteins, we performed similar transfection experiments in low-density hippocampal cultures at 9-11 DIV. Hippocampal neurons expressing ectopic PTBP1 or PTBP2 exhibited a markedly reduced density of PSD-95 puncta along their dendrites at 21 DIV (Fig. 1e,f) . These data, together with the results of our lentiviral experiments, indicate that either re-expression of PTBP1 or overexpression of PTBP2 is sufficient to repress PSD-95 protein expression in differentiated neurons.
We next tested whether the loss of the PTB proteins was sufficient to increase PSD-95 expression. Early knockdown of PTBP1 by shRNA lentivirus in primary cortical cultures at 0-4 DIV induced PTBP2 expression and the neurons appeared to differentiate normally. In contrast, depletion of PTBP2 caused a morphological deterioration and cell death at 5 DIV, indicating that PTBP2 is required early on for neuronal survival. If we infected the cultures with shRNA lentiviruses at 4 DIV, rather than earlier, these neurons survived until 9 DIV, when we analyzed the protein expression. In these conditions, PTBP2 knockdown led to a nearly twofold increase in PSD-95 protein expression ( Fig. 1g) . PTBP1 expression was already very low by 4 DIV, so knockdown of PTBP1only marginally increased PTBP2 expression and did not affect PSD-95 expression. Knockdown of both PTBP1 and PTBP2 yielded similar results to the single PTBP2 knockdown (Fig. 1g) . The specificity of this Ptbp2 shRNA was confirmed by coinfection of neurons with the lentivirus expressing Ptbp2 cDNA that was insensitive to the Ptbp2 shRNA. PTBP2 transduction in these neurons reversed the effect of the Ptbp2 shRNA ( Supplementary  Fig. 3 ). A different shRNA targeting different Ptbp2 sequences also enhanced PSD-95 expression ( Supplementary Fig. 4) , indicating that the change in PSD-95 was not a result of an off-target effect of the shRNA. To confirm that the increase in PSD-95 is an autonomous effect in the cells depleted of PTBP2, we transfected primary cortical neurons with both Ptbp2 shRNA and GFP plasmids at 4 DIV. Under these conditions, the PTBP2-deficient neurons exhibited enhanced npg a r t I C l e S PSD-95 expression compared with neighboring untransfected neurons ( Fig. 1h) . These data suggest that the PTB proteins are negative regulators of PSD-95 protein expression.
PTB proteins repress synapse maturation
PSD-95 is involved in the maturation of excitatory synapses and is important for the synaptic targeting of AMPA-type glutamate receptors. Overexpression of PSD-95 in hippocampal cultures augments the amplitude and frequency of AMPA receptormediated miniature excitatory postsynaptic currents (mEPSCs) and promotes synapse maturation 5 . We therefore examined whether PTBP1 and PTBP2 can regulate PSD-95-related neuronal physiology. In repressing PSD-95, re-expression of the PTB proteins in mature neurons should have potent, inhibitory effects on excitatory synaptic transmission. To examine this, we recorded mEPSCs from hippocampal neurons transfected with either Ptbp1 and Ptbp2 expression plasmids or control plasmids. Indeed, we found that transfection of cells with both Ptbp1 and GFP expression plasmids led to an approximately twofold decrease in both the amplitude and frequency of mEPSCs compared with non-transfected neurons from the same cultures ( Fig. 2) . Overexpression of PTBP2 had a similar effect ( Fig. 2b,d) , whereas transfection of a pcDNA control plasmid with GFP had no effect on either mEPSC amplitude or frequency ( Fig. 2c,d) . Thus, downregulation of PSD-95 protein expression following re-expression of the PTB proteins in mature neurons resulted in substantial deficits in excitatory synaptic transmission.
We also tested whether there were morphological changes that accompanied PSD-95 reduction after PTBP1 and PTBP2 expression in differentiated neurons. PSD-95 was previously shown to increase the number and size of dendritic spines 5 . We again co-transfected dissociated hippocampal cultures with Ptbp1, Ptbp2 and GFP expression plasmids and then examined the spine morphology of transfected neurons via GFP fluorescence. Compared with control neurons, neurons transfected with either the Ptbp1 or Ptbp2 expression plasmids had a lower spine density (Fig. 3) . These spines also did not appear to be as mature, with many having small or no spine heads. Indeed, PTBP1 or PTBP2 expression markedly reduced the density of mushroom-shaped dendritic spines ( Fig. 3b,d) . These data indicate that the PTB proteins inhibit PSD-95 expression and PSD-95-mediated synapse maturation.
Psd-95 exon 18 splicing is regulated by the PTB proteins
The PTB proteins are known to control many neuronally regulated exons. Examining the Psd-95 gene locus, we found multiple blocks of intronic sequence flanking exon 18 that are conserved across mammalian species (Fig. 4a) , a common feature of highly regulated exons [21] [22] [23] [24] . PSD-93 and SAP102, which are not repressed by the PTB proteins, do not have a paralogous exon and flanking introns. The 914-nucleotide intron (intron 17) upstream of exon 18 of Psd-95 contains 20 non-overlapping tracts of ten or more nucleotides that contain only cytosine or uracil, and many of these sequences are conserved across mammalian species. These polypyrimidine elements are a hallmark of exons that are regulated by PTBP1 (refs. [25] [26] [27] . To confirm the binding of PTBP1 to this region, we performed electrophoretic mobility shift assays (EMSA) with a 19-nucleotide pyrimidine-rich RNA of intron 17 (element A) found immediately upstream of the putative exon 18 branch point ( Fig. 4a,b ). This is a common location for repressive PTB-binding sites 28 . Recombinant His-tagged PTBP1 protein efficiently bound to RNA probe 1, which contained element A, quantitatively shifting it into a slowly migrating complex. The sequence specificity of the interaction was confirmed in experiments showing that PTBP1 binding could be competed with cold wild-type element A RNA (probe 1), but not with a mutant RNA (probe 2) ( Fig. 4b) .
The binding of PTBP1 to this intron was also observed in a genomewide mapping of PTBP1-binding sites by crosslinking and immunoprecipitation of HeLa cell RNA 29 . Notably, HeLa cells express low levels of PSD-95 mRNA. To confirm the in vivo binding of the PTB proteins in brain, we performed crosslinking and immunoprecipitation followed by reverse transcription (RT)-PCR on embryonic day 16 (E16) mouse brain. Immunoprecipitation with either antibodies to PTBP1 or PTBP2, but not antibody to Flag, pulled down Psd-95 pre-mRNA containing element A (Supplementary Fig. 5 ). In contrast, neither the related Sap102 (also known as Dlg3) transcript nor the Gapdh transcript was co-precipitated with the PTB proteins. These results indicate that Psd-95 exon 18 is likely to be a direct target of the PTB proteins.
To determine whether exon 18 of Psd-95 is regulated by the PTB proteins, we performed RNA interference (RNAi)-mediated knockdown of the protein in mouse neuroblastoma Neuro2a (N2a) cells. npg a r t I C l e S Similar to HeLa cells, N2a and many other cell lines express Psd-95 mRNA, albeit in smaller amounts than in neurons. Reducing PTBP1 protein levels by 75% increased exon 18 splicing from 66% to 82% (Fig. 4c) . A second shRNA targeting a different Ptbp1 sequence also stimulated exon 18, indicating that the change in splicing was a result of PTBP1 depletion and not an off-target effect ( Supplementary  Fig. 6 ). As seen previously, PTBP1 depletion induced PTBP2 protein expression [10] [11] [12] . Knocking down both PTB proteins further increased exon 18 inclusion to 90% (Fig. 4c) . We also performed the converse experiment of transiently expressing Flag-tagged Ptbp1 or Ptbp2 in N2a cells. Consistent with PTB protein depletion, overexpression of PTBP1 or PTBP2 repressed exon 18 inclusion from 66% to either 46% or 55%, respectively ( Fig. 4d) . Ectopic expression of RNAi-resistant Ptbp1 or Ptbp2 cDNAs also rescued the effects of PTBP1 and PTBP2 knockdown on exon 18 splicing ( Supplementary Fig. 7) . Thus, both PTBP1 and PTBP2 repress exon 18 splicing, with PTBP1 possibly having a stronger effect in N2a cells.
To further confirm that exon 18 repression was as a result of the direct binding of the PTB proteins, we inserted the sequence of element A into a minigene construct (DS4) immediately upstream of the alternative exon branch point 25 and expressed this plasmid in cells. As seen previously, the splicing of DS4 itself was only weakly inhibited by coexpressed PTBP1. The addition of element A greatly increased repression by PTBP1 (Fig. 4e) . In contrast, insertion of a mutant element (Probe 2; Fig. 4b ) did not alter DS4's response to PTBP1. Note that there are multiple potential PTB-binding sites in this region in addition to element A. These data indicate that the PTB proteins repress exon 18 splicing via an interaction with its upstream intronic sequences.
The Psd-95Dexon 18 isoform is a conserved NMD target Skipping of exon 18 shifts the PSD-95 reading frame and results in premature translation termination at a conserved stop codon in exon 19 (Fig. 5) . In the absence of exon 18 (Psd-95∆exon 18 isoform), the reading frame terminates 80 nucleotides upstream of the exon 19-20 splice junction, making the transcript a candidate for degradation by 13, 14 . Indeed, exon 18 was previously identified in a large-scale screen for NMD-inducing splicing events 16 .
As a result of its loss to NMD, the Psd-95∆exon 18 isoform should be produced at higher levels than are observed in steady-state mRNA. Transcripts that are subject to NMD can be stabilized by blocking translation because initial translation is required to trigger NMD 30 . To confirm that the Psd-95∆exon 18 transcript was targeted by NMD, we treated N2a cells with the translation elongation inhibitor cycloheximide. This treatment led to an increase in the Psd-95∆exon 18 isoform without affecting the full-length isoform (Fig. 5b) . We also examined Psd-95∆exon 18 isoform levels after knocking down the essential NMD factor Upf1. Depletion of UPF1 protein expression by 52 -70% using several different shRNAs led to a 2.6-3.2-fold increase in the level of Psd-95∆exon 18 isoform, but had minimal effects on the full-length isoform (Fig. 5d) . Thus, the Psd-95∆exon 18 isoform is produced at substantial levels in cells, but is then degraded by NMD in N2a cells.
Psd-95 mRNA is actively transcribed, but is lost to AS-NMD PSD-95 protein expression is induced during neuronal maturation 31 , but its mRNA expression and splicing during early development have not been well examined. To track PSD-95 and PTB protein expression in the developing brain, we isolated protein and RNA from dissected cerebral cortices at various developmental stages. PTBP1 protein was most abundant from E12-14 and then decreased at E14-16, with a second drop in expression after birth (Fig. 6) . PTBP2 protein was present at E12 and increased through E18 as PTBP1 expression decreased (Fig. 6a,d) . Although PTBP2 was expressed in the adult brain, we found that its expression was highest at E18 and then declined after birth. Psd-95 steady-state mRNA was readily detectable at E12 when 38% was the Psd-95∆exon 18 isoform, although its real splicing ratio is presumably underestimated because of NMD (Fig. 6b,d) . There was a notable increase in the full-length transcript between E14 and E16, concurrent with the drop in PTBP1 protein (Fig. 6d) . An additional postnatal increase in the full-length transcript coincided with the downregulation of both PTB proteins after birth (Fig. 6d) . Thus, Psd-95 is transcribed in the embryonic brain, but exon 18 is repressed when the PTB proteins are present.
PSD-95 protein becomes detectable from E16 and then exhibits a steady increase in expression after birth, in parallel with the increase in full-length mRNA.
To determine whether the PTB protein-mediated repression of PSD-95 protein expression was a result of changes in Psd-95 splicing, we re-examined the PTB lentivirus-infected cells. We infected primary cortical neurons with increasing doses of PTBP1-expressing lentivirus to counteract the loss of the PTB proteins during development. At 12 DIV, control cultures expressing GFP alone exhibited nearly 100% exon 18 inclusion and expressed an amount of PSD-95 protein similar to that expressed by mock-infected cultures (Fig. 6c) . In cultures infected with PTBP1-expressing virus, exon 18 inclusion was reduced to 89, 77 and 50% with increasing dose of PTBP1 (Fig. 6c) . This was accompanied by parallel decreases in full-length transcript and PSD-95 protein, similar to the pattern of expression during embryonic development (Fig. 6a,c) . These data indicate that the PTBP1 and PTBP2 proteins prevent accumulation of the productive full-length Psd-95 transcript early in development. The loss of the PTB proteins during neural maturation is necessary for exon 18 splicing and accumulation of the full-length transcript.
To further confirm the role of the PTB proteins and NMD in controlling PSD-95 expression, we examined NMD activity in primary cortical cultures. PTBP1, PTBP2 and PSD-95 protein expression were assayed as the cultures differentiated and matured, and their expression was consistent with the levels observed in vivo. PTBP1 protein expression was high at 0 DIV when neurons were dissected from mouse E15 cerebral cortex, but began to decrease by 3 DIV, and declined to negligible levels by 13 DIV (Fig. 7a) . As expected, PTBP2 protein expression increased from 0 DIV to 5 DIV, as the PTBP1 level dropped, and then declined with further maturation. PSD-95 protein expression increased when both PTBP1 and PTBP2 protein expression decreased. We then measured the splicing of Psd-95 exon 18 in these cultures with and without cycloheximide treatment to block NMD. Without cycloheximide, the amount of Psd-95∆exon 18 isoform decreased from about 12% of the total Psd-95 mRNA at 2 DIV to approximately 2% at 13 DIV (Fig. 7b) . Cycloheximide treatment markedly stabilized the Psd-95∆exon 18 mRNA isoform without affecting the full-length isoform. Under these conditions, exon 18 was Fold change * … npg a r t I C l e S skipped in nearly 50% of the mRNA at 2 DIV (corresponding to E17 in vivo). Thus, the true percentage of exon 18 skipping in these cultures is underestimated because of the loss of the isoform to NMD. Notably, the amount of Psd-95∆exon 18 mRNA stabilized by cycloheximide decreased as the cells matured. Accounting for NMD, the splicing of exon 18 strongly increased over time, in parallel with the loss of the PTBP1 and PTBP2 proteins.
To confirm that the Psd-95∆exon 18 isoform that was lost to NMD early in differentiation was being generated through the action of PTBP2, we transduced a Ptbp2-targeted shRNA into differentiating neurons and treated them with cycloheximide. As expected, depletion of PTBP2 protein from primary cortical neurons at 4 DIV increased exon 18 splicing (Supplementary Fig. 8 ). This increase was also observed and was more robust (from 63 to 84%) when NMD was blocked by cycloheximide treatment. These PTBP2deficient neurons at 4 DIV skipped exon 18 to the same degree as wild-type neurons at 10 DIV, when the PTBP2 level was much lower.
Thus, at early times, the Psd-95∆exon 18 isoform lost to NMD is generated by PTBP2. As the PTB proteins are depleted during neural development, exon 18 splicing increases and less Psd-95 mRNA is targeted for decay.
To examine NMD of the Psd-95∆exon 18 isoform in vivo, we dissected cortices from Upf2 conditional knockout mice. UPF2 is an essential factor in most nonsense-mediated decay, and similar to Upf1, Upf2 −/− mice die embryonically 18, 32 . To generate mice with a Upf2 null mutation in the nervous system, we crossed mice carrying a conditional loxPflanked Upf2 allele (Upf2 loxP/loxP ) 18 with Emx1-cre mice. The Emx1-cre gene expresses Cre recombinase specifically in excitatory neurons of cerebral cortex, leading to deletion of Upf2 only in these cells 33 . Ablation of Upf2 in these neurons stabilized the Psd-95∆exon 18 isoform in both E15.5 and E18.5 cerebral cortices (Fig. 7c) . In cortex lacking UPF2, the Psd-95∆exon 18 isoform accounted for 60% and 46% of total PSD-95 transcript at E15.5 and E18.5, respectively, whereas this isoform accounted for only 17% and 13% of the total PSD-95 transcript in wildtype animals. Similarly to the results in cell culture, younger embryonic neurons excluded exon 18 to a higher degree than mature cells. Thus, Psd-95 mRNA is highly transcribed during embryonic development, but is actively degraded as a result of AS-NMD. npg a r t I C l e S DISCUSSION PSD-95 expression is enhanced at a late time point in neural development to promote spine maturation, stabilize excitatory synapses and enhance AMPA receptor insertion in the synapse [5] [6] [7] [8] 34 . We found that, in immature neurons, PSD-95 is under stringent post-transcriptional repression that is mediated by the two RNA-binding proteins PTBP1 and PTBP2. These proteins target the Psd-95 transcript to the NMD pathway by altering the splicing of exon 18. The PTB proteins limit PSD-95 expression in immature neurons, where abundant expression of PSD-95 could be deleterious. For example, overly abundant PSD-95 might result in precocious stabilization of early generated synapses and limit the fine-tuning of connections during synaptic pruning. We found that the increase in PSD-95 expression during development required the sequential downregulation of PTBP1 and PTBP2. Consistent with the idea that PTB inhibition of PSD-95 expression has an important role in synapse maturation, re-expression of PTBP1 or PTBP2 strongly repressed AMPA receptor-mediated mEPSCs and reduced mature spine density in hippocampal neurons. Thus, the downregulation of PTBP1 and PTBP2 during development is necessary for PSD-95 expression and synapse maturation.
Tissue specific expression enforced by AS-NMD
Alternative splicing of exon 18 may have been acquired as a means of restricting expression of the mammalian Psd-95 gene to neurons. The ancestral homolog of PSD-95 in invertebrates, discs large 1, is expressed in epithelial cells and other non-neuronal cell types of Caenorhabditis elegans and Drosophila 35, 36 . These invertebrate genes do not have a region that is equivalent to mouse exon 18. All mammals have an exon 18 equivalent, with conserved flanking introns, although there is not a clearly homologous exon in other vertebrates. Given that PTBP1 is widely expressed in non-neuronal cells in mammals, PSD-95 is largely repressed outside of neurons. During development, the abundance of the productive Psd-95 transcript increased as the PTB proteins were depleted (Fig. 6d) . Rather than modifying its activity through changes in protein sequence, the alternative splicing of exon 18 determines the overall level of Psd-95 mRNA, similar to the output of transcriptional control. This process of alternative splicing coupled with NMD is known to maintain the homeostatic levels of splicing factors in cultured cells, but for PSD-95 this mechanism modulates its expression during development. The NMD pathway itself may be subject to developmental regulation, as miR-128 represses Upf1 mRNA expression during neuronal differentiation, leading to increased levels of many NMDtargeted transcripts 37 . We found that the loss of UPF1 occurred later in development than the changes in PSD-95 that we observed (data not shown). We did not observe an increase in the Psd-95∆exon 18 transcript during development that might result from a depletion of NMD activity (Fig. 6b) . Presumably, the PTB proteins are depleted and there is little Psd-95∆exon 18 transcript to be stabilized by the time UPF1 levels decline.
It is possible that the remaining PTBP2 present in adult neurons could affect activity-dependent PSD-95 expression. However, we have no evidence for this. Cortical cultures stimulated with 50 µM glutamate for 5 min exhibited reduced PSD-95 protein expression by 1 h 38 ; however, these cells did not show changes in PTBP2 protein or Psd-95∆exon 18 transcript expression (data not shown). Similarly, mice that have undergone kainite-induced seizure have reduced PSD-95 in their hippocampi 39 . Under these conditions, we did not observe increased levels of PTBP2. Thus, the role of PTBP1 and PTBP2 may be restricted to the developmental regulation of PSD-95 and not its subsequent control in the adult.
The splicing of a pre-mRNA has been shown to affect its subsequent localization and translation [40] [41] [42] . In mature neurons, where exon 18 is fully included, some Psd-95 mRNA is localized at synapses, where it is translationally controlled 43, 44 . Most of the Psd-95∆exon 18 transcript was expressed at an early stage of synapse formation and it is unclear whether it can be targeted to synapses. However, it appears unlikely that the Psd-95∆exon 18 transcript is translated into stable protein.
We were not able to detect a putative PSD-95∆exon 18 protein in the E15.5 or E18.5 neocortices of Upf2 conditional knockout mice in which the Psd-95∆exon 18 transcript was substantially stabilized. Similarly in mature neurons, when the Psd-95∆exon 18 transcript was increased via re-expression of PTBP1, its protein product remained undetectable (Fig. 6c) . The PSD-95∆exon 18 protein could have a high turnover rate, be inefficiently translated or both.
Other neuronal mRNAs have structures that implicate splicing and NMD in their posttranscriptional control. The Arc mRNA contains introns in its 3′ UTR, making it a 'constitutive' NMD target that always carries the eIF4A3 protein needed for inducing decay. This property is thought to limit Arc translation to precise times and locations in mature neurons 45 . Earlier in development, Robo3, a Slit receptor, has two spliced isoforms (Robo3.1 and Robo3.2) that control the guidance of spinal commissural axons as they cross the midline 46 . Robo3.1 protein mediates Slit attraction, whereas Robo3.2 mediates repulsion from Slit protein expressed at the midline. Robo3.2 arises from an mRNA whose translation terminates in a retained intron 46, 47 , making it a potential NMD target. Factors controlling the splicing of Arc and Robo3 have not yet been identified, but the similar combination of post-transcriptional controls seen for PSD-95, Arc and Robo3 imply that this mechanism of neuronal gene regulation may be widespread.
PTBPs define three phases of neuronal differentiation
The changes in PTBP1 and PTBP2 protein expression define three phases of splicing regulation during neuronal differentiation. PTBP1 target exons are repressed in neural progenitor cells. Some exons that are more sensitive to PTBP1 than to PTBP2 are induced early in development as PTBP1 levels drop 10, 11 . Other exons that are affected by both PTBP1 and PTBP2 proteins, such as exon 18, are not spliced strongly until later in development, when the PTBP2 level is reduced. Exons that are repressed by both proteins have also been identified in RNAi knockdown experiments in tissue culture cells 10, 12 . The ordered expression of these related splicing regulators allows neuronal stem cells, early differentiating neurons and cells undergoing synaptic maturation to each be defined by a different splicing program.
Except for its timing, the control of PSD-95 is similar to the induction of PTBP2 expression during neuronal differentiation. PTBP2 transcripts are expressed in neuronal progenitor cells, but PTBP2 exon 10 is repressed in these cells by the PTBP1 protein [10] [11] [12] . The absence of exon 10 introduces a frameshift in the mRNA targeting it to the NMD pathway. During differentiation, the downregulation of PTBP1 induces both the splicing of exon 10 from Ptbp2 and the expression of PTBP2 protein 10 . This same process apparently acts on PSD-95, except that both PTBP1 and PTBP2 proteins affect Psd-95 transcripts. This results in continued repression of PSD-95 through an intermediate period when PTBP1 protein levels are depleted, but PTBP2 protein levels are still high. Induction of PSD-95 then occurs when PTBP2 protein expression is reduced after birth (Supplementary Fig. 9 ).
Ptbp2 exon 10 splicing is also promoted by the increased expression of another splicing regulator, NSR100, during neural development and is likely affected by multiple additional factors 48 . It will be interesting to determine which other splicing regulators can affect Psd-95 exon 18 npg a r t I C l e S splicing, including NSR100 and factors that are known to be expressed in mature neurons, such as the Nova or Fox family members.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
